Abstracts tagged "Cancer treatments"

Abstract Number: 253 • 2019 ACR/ARP Annual Meeting
A Systematic Review and Meta-analysis of Observational Studies Reporting on the Use of Checkpoint Inhibitors in Patients with Cancer and Pre-existing Autoimmune Disease
Maria Lopez-Olivo¹, Noha Abdel-Wahab ¹ and Maria E. Suárez-Almazor ², ¹The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Department of Rheumatology/Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX , USA., Houston, TX
Background/Purpose: Immune checkpoint inhibitors (ICI) are increasingly used in the treatment of cancer. To date, no clinical trials exist evaluating the use of ICI in…
Abstract Number: 1810 • 2019 ACR/ARP Annual Meeting
Rheumatic Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Retrospective, Pharmacovigilance Study
Céline Anquetil¹, Olivier Benveniste ¹, Javid ‎ Moslehi ², Douglas Johnson ², Bénédicte lebrun-vignes ¹, Olivier Lambotte ³, Joe-Elie Selam ⁴, Jean-Philippe Spano ⁵ and Yves Allenbach ¹, ¹Sorbonne Université, Paris, France, ²Vanderbilt, Nashville, ³APHP Médecine Interne/Immunologie Clinique, Hôpital Bicêtre, Paris, France. Université Paris Sud 11 – INSERM U1184 - CEA, Immunology of Viral Infections and Autoimmune Diseases, IDMIT Department, IBFJ, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Paris, France, ⁴Sorbonne université, Paris, ⁵Sorbonne Université, Paris, French Guiana
Background/Purpose: Monoclonal antibodies targeting co-inhibitory immune checkpoints (PD-1/PDL1 axis or CTLA-4) showed unprecedented clinical activity in several types of cancer by restoring antitumor immune responses.…
Abstract Number: 2137 • 2019 ACR/ARP Annual Meeting
Overall Survival in Patients with PD-1 Inhibitor-related Inflammatory Arthritis and Metastatic Melanoma
Michael Richter¹, Jacob Orme ², Heidi Finnes ³ and Uma Thanarajasingam ⁴, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Hematology and Oncology, Mayo Clinic, Rochester, MN, ³Department of Pharmacy, Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: The development of de novo inflammatory arthritis (IA) occurs in 2-4% of all patients with cancer treated with programmed cell death protein 1 (PD-1)…
Abstract Number: 2158 • 2019 ACR/ARP Annual Meeting
Rheumatic Immune Related Adverse Events Associated with Cancer Immunotherapy: A Nationwide Multi-centre Canadian Cohort from the Canadian Research Group of Rheumatology in Immuno-oncology (CanRIO)
Janet Roberts¹, Daniel Ennis ², Marie Hudson ³, Carrie Ye ⁴, Alexandra Saltman ⁵, Sabrina Hoa ⁶, Janet Pope ⁷, Megan Himmel ², Nancy Maltez ⁸, Aurore Fifi-Mah ⁹, Annaliese Tisseverasinghe ¹⁰, Robert Rottapel ¹¹, Karam Al Jumaily ¹², Christina Ly ¹³, Liliana Cartagena ¹⁴ and Shahin Jamal ¹⁵, ¹Dalhousie University, Halifax, NS, Canada, ²University of Toronto, Toronto, ON, Canada, ³Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵University of Toronto, Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto, ON, Canada, ⁶University of Montreal, Montreal, QC, Canada, ⁷Western University, London, ON, Canada, ⁸University of Ottawa, Ottawa, ON, Canada, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰University of Manitoba, Winnipeg, MB, Canada, ¹¹University of Toronto, Toronto, Canada, ¹²University of Alberta, edmonton, Canada, ¹³McGill University, Montreal, Canada, ¹⁴Arthritis Research Canada, Vancouver, Canada, ¹⁵University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy by harnessing the immune system to fight cancer. They are associated with the development of autoimmune…
Abstract Number: 356 • 2018 ACR/ARHP Annual Meeting
Immune Related Adverse Events from Immune Checkpoint Inhibitors: A Retrospective Analysis from 2004-2017 at the University of North Carolina at Chapel Hill
Rachel Romero¹, Todd Schwartz², Shruti Saxena Beem¹ and Rumey Ishizawar³, ¹Division of Rheumatology, Allergy and Immunology and the Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Division of Rheumatology, Allergy, and Immunology and Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Immune checkpoint inhibitors (ICI) targeting CTLA-4, such as ipilimumab (anti-CTLA4), or PD-1/PD-L1, such as nivolumab and pembrolizumab are increasingly utilized in a wide variety…
Abstract Number: 359 • 2018 ACR/ARHP Annual Meeting
Characterization of Lymphoid Cells in Synovial Fluid from Cancer Patients with Immunotherapy-Induced Arthritis
Sang Kim¹, Jean Tayar¹, Huifang Lu¹, Jennifer Wang², Don Gibbons³, Guillermo Garcia-Manero⁴, Patrick Hwu⁵, Adi Diab⁵ and Roza Nurieva⁶, ¹General Internal Medicine (Rheumatology), MD Anderson Cancer Center, Houston, TX, ²Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, ³Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, ⁴Leukemia, MD Anderson Cancer Center, Houston, TX, ⁵Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, ⁶Immunology, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Checkpoint inhibitors (ICIs) are revolutionizing cancer treatment; however, ICI therapy is associated with immune-related adverse events (irAEs). irAEs can be life-threatening and/or severely impair…
Abstract Number: 1914 • 2018 ACR/ARHP Annual Meeting
Rheumatic Syndromes Associated with Immune-Checkpoint Inhibitors: A Single-Center Cohort of 61 Patients
Michael Richter¹, Cynthia S. Crowson², Lisa Kottschade³, Heidi Finnes³, Svetomir N. Markovic⁴ and Uma Thanarajasingam⁵, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Oncology, Mayo Clinic, Rochester, MN, ⁴Department of Medicine and Oncology, Mayo Clinic, Rochester, MN, ⁵Department of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Rheumatologists are increasingly called upon to manage the autoimmune side effects of immune-checkpoint inhibitors (ICIs). However, these new entities are poorly understood and treatment…
Abstract Number: 1182 • 2017 ACR/ARHP Annual Meeting
Autoantibody Profiling in Prostvac and Ipilimumab Treated Prostate Cancer Patients Reveals Potential Biomarkers of Immune-Related Adverse Events
Petra Budde¹, Jennifer Marte², Hans-Dieter Zucht¹, Saurabh Bhandari¹, Manuel Tuschen¹, Peter Schulz-Knappe¹, James Gulley², Christopher Heery³, Ravi Madan² and Jeffrey Schlom², ¹Protagen AG, Dortmund, Germany, ²National Cancer Institute, National Institutes of Health, Bethesda, MD, ³Bavarian Nordic, Inc., Morrisville, NC
Background/Purpose: Autoantibodies (AAB) targeting self-antigens can be found in two clinically and immunologically opposing diseases, autoimmune diseases and cancer. While in autoimmune diseases, the immune…
Abstract Number: 1227 • 2017 ACR/ARHP Annual Meeting
Osteoporosis and Breast Cancer: Can FRAX-Based Risk Factors Accurately Predict Further Fractures at This Setting?
Salvador López-Salguero¹, Laura Ranieri², Juan Carlos Ordoñez³, Mariano Andrés^4,5, Jose Ponce⁶ and Isabel Ibero², ¹Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, ²Reumatología, Dpt. Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ³RHEUMATOLOGY, Dpt. Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ⁴Dpt. Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ⁵Universidad Miguel Hernández, Elche, Spain, ⁶Oncología, Dpt. Oncology, Hospital General Universitario Alicante, Alicante, Spain
Background/Purpose: Women with breast cáncer (BC) are at risk for the development of bone loss and osteoporosis (OP) mainly due to adjuvant therapies, as aromatase…
Abstract Number: 2155 • 2017 ACR/ARHP Annual Meeting
Myositis As a Complication of Checkpoint Blockade at a Comprehensive Cancer Center
Mohsin Shah¹, Jean Tayar¹, Noha Abdel-Wahab^1,2 and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Rheumatology and Rehabilitation Department, Assiut University Hospitals, Assiut, Egypt, Assiut, Egypt
Background/Purpose: Immune checkpoint inhibitor therapy (ICI) has surfaced as a successful and robust treatment option in the fight to end cancer. As we gain more…
Abstract Number: 1340 • 2016 ACR/ARHP Annual Meeting
Type and Frequency of Immune-Related Adverse Reactions in Patients Treated with Pembrolizumab (Keytruda), a Monoclonal Antibody Directed Against PD-1, in Advanced Melanoma at a Single Institution
Olga Pinkston¹, Florentina Berianu¹ and Benjamin Wang², ¹Rheumatology, Mayo Clinic, Jacksonville, FL, ²Division of Rheumatology, Mayo Clinic, Jacksonville, FL
Background/Purpose: Although immune checkpoint inhibitors improve survival in patients with melanoma and other cancers, the alterations to the immune system induced by these medications can…
Abstract Number: 1341 • 2016 ACR/ARHP Annual Meeting
Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Literature Review
Laura Cappelli¹, Anna Kristina Gutierrez², Ami A. Shah³ and Clifton Bingham III⁴, ¹Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins University, Baltimore, MD
Rheumatic and Musculoskeletal Immune-Related Adverse Events due to Immune Checkpoint Inhibitors: A Systematic Literature Review Background/Purpose: Immune checkpoint inhibitors (ICI) are effective treatments for advanced…
Abstract Number: 2198 • 2014 ACR/ARHP Annual Meeting
The Aromatase Inhibitor Induced Musculoskeletal Syndrome: Is There a Potential Role of Osteoporosis Therapy and Menopause Timing?
Zsolt Kulcsar¹, Clinton Morgan², Peter Kaufman³, Jonathan Jones⁴ and William Rigby⁵, ¹Rheumatology/Leadership Preventive Medicine Residency, Dartmouth Hitchcock Medical Center, lebanon, NH, ²Hematology/Oncology, Dartmouth Hitchcock Medical Center, Lebanon, NH, ³Hematology/Oncology, Dartmouth Hitchcock Medical Center, lebanon, NH, ⁴Rheumatology Clinic, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ⁵Dartmouth-Hitchcock Medical Center and Dartmouth Medical School, Lebanon, NH
Background/Purpose: Aromatase Inhibitor (AI) therapy is the most effective hormonal treatment in post-menopausal estrogen receptor (ER) positive breast cancer. These patients may be seen by…
Abstract Number: 698 • 2013 ACR/ARHP Annual Meeting
Adverse Events With The Use Of Radiotherapy In Patients With Connective Tissue Diseases and Cancer: A Systematic Review and Meta-Analysis
Maria A. Lopez-Olivo¹, Juan A Martínez-López², Jean H. Tayar³, Mahesh Bavineni⁴ and Maria E. Suarez-Almazor⁵, ¹General Internal Medicine, University of Texas. M.D Anderson Cancer Center, Houston, TX, ²Rheumatology, Section for Autoimmune Diseases, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ³General Internal Medicine, University of Texs, MD Anderson Cancer Center, Houston, TX, ⁴Internal Medicine, Louisiana State University Lafayette, Lafayette, LA, ⁵The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: In the era of modern medicine, radiotherapy remains a cornerstone for the multi-modality cancer treatment. Methods: We conducted a comprehensive search for any study…
Abstract Number: 1932 • 2012 ACR/ARHP Annual Meeting
Clinical Features of an Aromatase Inhibitor Associated Syndrome Presenting As Rheumatoid Arthritis Ronald J. Anderson, MD, Brigham &Women’s Hospital
Ronald J. Anderson, Rheumatology/Admin B-3, Brigham & Womens Hospital, Boston, MA
Background/Purpose: The aromatase inhibitors (AI); anastrozole, letrozole and exemestane are used in the treatment of postmenopausal women with estrogen receptor positive breast cancer. Arthralgias occur…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].